

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Prout Samantha</u> (Last) (First) (Middle) <u>C/O AMICUS THERAPEUTICS, INC.</u> <u>3675 MARKET STREET</u> (Street) <u>PHILADELPHIA PA 19104</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/10/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS, INC. [FOLD]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Accounting Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock⁽¹⁾</u>	<u>137,003</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Options (right to buy)</u>	<u>(2)</u>	<u>03/26/2028</u>	<u>Common Stock</u>	<u>2,940</u>	<u>14.88</u>	<u>D</u>	
<u>Stock Options (right to buy)</u>	<u>(2)</u>	<u>01/02/2029</u>	<u>Common Stock</u>	<u>2,376</u>	<u>10.04</u>	<u>D</u>	
<u>Stock Options (right to buy)</u>	<u>(3)</u>	<u>01/02/2030</u>	<u>Common Stock</u>	<u>7,566</u>	<u>9.55</u>	<u>D</u>	
<u>Stock Options (right to buy)</u>	<u>(4)</u>	<u>04/15/2030</u>	<u>Common Stock</u>	<u>13,768</u>	<u>10.03</u>	<u>D</u>	
<u>Stock Options (right to buy)</u>	<u>(5)</u>	<u>01/04/2031</u>	<u>Common Stock</u>	<u>16,963</u>	<u>21.78</u>	<u>D</u>	
<u>Stock Options (right to buy)</u>	<u>(6)</u>	<u>01/14/2032</u>	<u>Common Stock</u>	<u>56,711</u>	<u>12.11</u>	<u>D</u>	
<u>Stock Options (right to buy)</u>	<u>(7)</u>	<u>01/03/2033</u>	<u>Common Stock</u>	<u>55,203</u>	<u>11.93</u>	<u>D</u>	

Explanation of Responses:

- The amount shown on this line represents Restricted Stock Units which will vest in varying quantities over the next four years, subject in each case to Ms. Prout's continued service with the Company through the applicable vesting dates.
- All of the options shown on this line are fully vested and exercisable.
- These options were granted on January 2, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 5,670 options are vested and exercisable and 1,896 remain unvested.
- These options were granted on April 15, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,878 options are vested and exercisable and 2,890 remain unvested.
- These options were granted on January 4, 2021, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,594 options are vested and exercisable and 6,369 remain unvested.
- These options were granted on January 14, 2022, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 21,263 options are vested and exercisable and 35,448 remain unvested.
- These options were granted on January 3, 2023, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. All of the options shown on this line are unvested.

Remarks:

/s/ Christian Formica,
Attorney-in-Fact

07/14/2023

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

The undersigned hereby constitutes and appoints each of Ellen Rosenberg, Daphne Quimi and Christian Formica, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

1. prepare and execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Amicus Therapeutics, Inc., a Delaware corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and file any such Form or amendment with the SEC and any stock exchange or similar authority, including filing this power of attorney with the SEC; and
4. take any other action necessary in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This power of attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of July, 2023.

/s/ Samantha Prout
Signature

Samantha Prout
Print Name